R&D | December 09, 2025
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Angelini Ventures has already invested €125 million in 22 startups
GV20 received an upfront payment and is eligible for additional milestone payments
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The antibody was designed and developed at Abzena’s Cambridge, UK,
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Subscribe To Our Newsletter & Stay Updated
